# Advanced Oncotherapy plc appoint Professor Steve Myers & Mr Hans von Celsing as Non-Executive Directors

- Link: https://www.directorstalkinterviews.com/advanced-oncotherapy-plc-appoint-professor-steve-myers-mr-hans-von-celsing-non-executive-directors/412722313
- Published: 2017-01-26T07:31:30+00:00
- Author: Giles Arbor

**Advanced Oncotherapy Plc** (LON:AVO), the developer of next-generation proton 
therapy systems for cancer treatment, announced today the appointment of Professor
Steve Myers OBE and Mr Hans von Celsing as Non-Executive Directors with immediate
effect. In addition, Mr von Celsing will become Senior Independent Non-Executive
Director. Professor Myers’ appointment follows the announcement of the Company’s
intention to do so, on 1 November 2016.

At the same time, Tim Lebus, Non-Executive Director, will stand down with immediate
effect.

Professor Steve Myers

Professor Myers has been part of the Advanced Oncotherapy Leadership Team since 
his appointment as Executive Chairman of the Company’s fully owned subsidiary ADAM
S.A., in November 2015. Before joining Advanced Oncotherapy, Professor Myers was
Head of Medical Applications at CERN in Geneva and before that, was Director of 
Accelerators and Technology at CERN. There, he was responsible for the operation
and exploitation of the whole accelerator complex, with particular emphasis on the
Large Hadron Collider (“LHC”) and the development of new projects and technologies.

He is a Fellow of the Royal Academy of Engineering, the Institute of Physics, the
European Physical Society and International Fellow of the American Physical Society.
He is internationally recognised for his engineering contributions and leadership
in the development of CERN’s particle colliders over the past 40 years, including
the Intersecting Storage Ring Accelerator, the Large Electron-Positron collider 
and the LHC.

Professor Myers has been awarded a number of international prizes including the 
EPS Edison Volta Prize and the Prince of Asturias Prize of Spain. He was awarded
an OBE in 2013 for services to science and technology. Professor Myers holds a number
of honorary degrees and advisory positions and is Chair of the Advisory Committees
of both the John Adams Accelerator Institute in Oxford and the Cockcroft Accelerator
Institute. He has published over 300 scientific papers.

Mr Hans von Celsing

Mr von Celsing was an Adviser to Mevion Medical Systems for eight years and supported
their international expansion in Europe and Asia. Mr von Celsing also joined Elekta,
as Executive Vice President, in its early stages in 1985. Elekta, a publicly quoted,
Swedish medical technology group, is the leading supplier of equipment instrumentation
and information systems for use in neuroscience, cancer care and oncology management.
Both Elekta and Mevion are active in the Radiation Oncology Technology market.

Mr von Celsing has held a number of Board level roles throughout his career, and
has particular expertise in the areas of life sciences, medical devices and diagnostics.
Mr von Celsing is currently Chairman of Clinical Laser Thermia Systems, a public
quoted medical technology company in Lund, Sweden. He is also Chairman of Gelexir
Healthcare Ltd, a medical technology company based in Manchester, Chairman of Partner
Fondkommission, an independent investment banking company based in Gothenburg, Sweden,
and Chairman of Peptonic Medical, a publicly quoted biopharmaceutical company in
Stockholm.

Mr von Celsing’s considerable experience in the growth of radiation therapy companies
and in corporate governance makes him ideally placed to join Advanced Oncotherapy
as Senior Independent Non-Executive Director.

> **Commenting, Michael Sinclair, Executive Chairman of Advanced Oncotherapy Plc
> said:** “Steve and Hans are hugely experienced in their respective fields. Steve’s
> background at CERN and his work with accelerator technology and the medical application
> of this technology have been invaluable to the business since he joined us in 
> 2015. Hans has a wealth of knowledge in the sector and his CV speaks for itself
> in terms of his experience at Board level. We are looking forward to having him
> join us and the value he will no doubt add to the team.
> “Finally, I would like to thank Tim Lebus for his immense contribution to the 
> Board over the last three and a half years. Tim’s experience in private equity
> and banking has been incredibly helpful as the company has progressed and we are
> very grateful for his guidance and we wish him well for the future.”
> **Commenting, Hans von Celsing, said:** “I am honoured to be asked to join the
> Advanced Oncotherapy Board as Senior Independent Non-Executive Director. The Company’s
> technology is truly amazing and promises to shape the next generation of radiation
> therapy equipment. What really impresses me is the quality of the team, the deep
> technical knowledge they have and the Company’s collaboration with CERN, the preeminent
> particle physics institute. The foundation is there for a great commercial success
> story in the medical technology field.”

Share on: